The key molecular targets are laminin and fibronectin at the vitreoretinal interface. Ocriplasmin cleaves these proteins, weakening the attachment between the vitreous and retina. This cleavage supports two linked effects: liquefaction of the vitreous gel and separation from the retinal surface. The significance is mechanical, because reducing abnormal attachment can lessen forces that distort the macular retina.
Vitreous liquefaction alone does not explain the full effect; release of the vitreoretinal interface is also important. When enzymatic cleavage disrupts laminin and fibronectin, the vitreous can separate rather than remain abnormally attached to the retina. This distinction helps explain why enzymatic vitreolysis is aimed at vitreomacular adhesion or traction, where attachment itself contributes to retinal distortion.
Neuroscience relevance comes from the retina’s identity as neural tissue. Changes at its interface with the vitreous can influence retinal shape and, consequently, visual function. Enzyme vitreous removal therefore connects molecular extracellular-matrix modification with a neural sensory structure. Studying the approach requires attention not only to gel alteration, but also to whether retinal distortion and interface-related effects are relieved.
At a high level, enzyme vitreous removal uses a proteolytic agent to modify the vitreoretinal interface, after which vitreous liquefaction and separation may occur. Ocriplasmin is an example identified for this purpose. The available description does not provide a detailed administration protocol, so the supported procedural concept is selective enzymatic alteration of abnormal attachment rather than a complete surgical removal workflow.
Clinical use is directed toward selected cases of vitreomacular adhesion or traction. These conditions are relevant because an abnormal attachment can maintain traction and retinal distortion at the vitreoretinal interface. By targeting that relationship enzymatically, the approach may address the underlying attachment without immediately requiring surgical vitrectomy, although the material supports use only in appropriately selected cases.
Compared with surgical vitrectomy, enzyme vitreous removal is described as minimally invasive and may reduce the need for an operation in appropriately selected cases. The comparison is therefore one of treatment strategy: an enzyme alters the gel and its attachment, whereas vitrectomy is the surgical alternative. The provided material does not establish that enzymatic treatment replaces surgery in every patient.